← Russell 3000 cross-section

OBIO Orchestra BioMed Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$316m
Revenue TTM
$32m
Net income TTM
$-59m
Free cash flow
$-59m
Composite score
Sector rank
#2629

Valuation

P / E
EV / EBITDA
EV / sales
6.4
FCF yield
-18.71%
Earnings yield vs 10-yr
-23.41pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-184.6%
EBITDA margin
-180.3%
ROE
-305.5%
ROIC
Revenue growth
986.1%

Insider activity, last 90 days

Net open-market
$-0.15m
Buyers
2
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We have funded our operations primarily through the issuance of our common stock, convertible preferred stock, and warrants, as well as proceeds from the Business Combination, our prior Terumo Agreement (as defined below) and the Termination and ROFR Agreement (as defined below), borrowings under debt arrangements, the sale of future revenues, sale of strategic investments, and, to a lesser extent, product revenue from our subsidiary, FreeHold Surgical, LLC. Cost of Product Revenue and Gross Margin Cost of product revenue consists primarily of costs of finished goods components for use in FreeHold’s products and assembled, warehoused and inventoried by a third-party vendor. …Orchestra BioMed Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →